Skip to content

ONCOPATH

Active Private limited companyfounded 2015active for 11 yearsRue Edmond Van Volxem (W-B) 13, 1440 Braine-le-ChâteauKBO/BCE: BE 0568.915.292

Lifetime

11 annual accounts with figures on one time axis
peak of €164,263 in 2025
€164,263▲ 75.0%
lowest -€29,214 in 2023
€85,312▲ 340%
peak of €210,912 in 2022
€197,897▼ 1.6%
€220,958▲ 74.6%
Board1 name since 2015
1 director
Documentsfilings and deeds
14-10-202675 days late
2025micro format
Gross margin from €93,888 to €164,263Result from €19,388 to €85,312Dividend €88,500Debts from €126,558 to €220,958Cash from €145 to €71

Key points

from the 2025 annual accounts

Equity

€197,897 ▼ 1.6%
201,0852024+85,312Profit-88,500Dividend197,8972025

ONCOPATH paid out €88,500 in dividends. That is 104% of the 2025 profit.

Result

€85,312 ▲ 340%
€19,4002024€85,3002025

The result rose in 2025 from €19,388 to €85,312.

Turnover

≈ €310,000 estimated

The accounts state no turnover.

Debts

€220,958 ▲ 74.6%
Other debts
+88,500
Taxes and wages
+33,754
The rest
-27,854

Debts rose by €94,400 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Liquidity

1.58 was 5.13 in 2024

Short-term debts rose from €33,586 to €184,958.

Filings

11 annual accounts 75 days
AprilJune31 JulyOctober201520202025

Latest accounts filed late: after the legal deadline.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 34,728 companies had the same profile as ONCOPATH has now. Each dot stands for 87 companies, two years later.

95.2%
were still trading
4.0%
stopped another way
0.7%
went bankrupt
  • Micro
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 34,728 companies, not a prediction for ONCOPATH. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • all the sharesdeed of 17-11-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0568915292
changes role from manager to director Discharge granted to · General meeting of 28-12-2023 · Gazette deed
Registered office moved from Waterloo to Braine-le-Château The registered office moved from Chaussée de Tervuren 113, 1410 Waterloo to RUE EDMOND VAN VOLXEM 13 1440 BRAINE-LE-CHATEAU · holds all the shares · General meeting of 15-09-2020 · Gazette deed
Registered office moved from Anderlecht to Waterloo Chaussee De Tervueren The registered office moved from SQUARE JEAN HAYEZ, 22 ET 4 BTE 4 1070 ANDERLECHT to 1410 WATERLOO CHAUSSEE DE TERVUEREN 113 · General meeting of 18-05-2017 · Gazette deed
All 26 events

Comparable companies

same main activity, similar in size and age
Company
ONCOPATH Braine-le-Château €418,854 €164,263 47.2% -
Claravista new La Hulpe €434,306 €157,514 2.5% -
EUROGYN Nivelles €372,389 €172,567 5.5% -
CABINET MEDICAL DOCTEUR MOINY Nivelles €413,346 €148,441 9.6% -
DOCTEUR P.MATHONET Lasne €479,347 €175,669 20.9% -
DR. JOHANNES RUIGE ENDOCRINOLOGIE EN DIABETOLOGIE Sint-Niklaas €422,217 €161,739 85.6% -
DOKTER JOHAN HELLINCKX, PEDIATER Brasschaat €421,019 €168,047 90.7% -

These companies have the same main activity as ONCOPATH: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €372,000 and €479,000, founded between 2013 and 2016.

Official details

Source: KBO
Status
Active since 21-01-2015Normal situation
Activity
Specialist medical practiceNACE 86220and 2 others
Establishment unit
2.241.269.6271440 Braine-le-Château, registered on 22-04-2015
Financial year end
31 December
Peppol
Reachable since 02-11-2025
Company details

Annual accounts 2025

€418,854▲ 27.8%
Filing
Filed on 14-10-2026
Financials

Insights on ONCOPATH

ONCOPATH files the micro format. That format states no turnover. The gross margin rose from €67,275 in 2015 to €164,263 in 2025.

The balance sheet grew most from 2016 to 2018 through fixed assets.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about ONCOPATH

What is the company number of ONCOPATH?
The company number of ONCOPATH is 0568.915.292. The VAT number is the same number with BE in front: BE 0568.915.292.
Where is ONCOPATH based?
The registered office is at Rue Edmond Van Volxem (W-B) 13, 1440 Braine-le-Château.Company details
What does ONCOPATH do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of ONCOPATH?
ONCOPATH is a private limited company (BV).
When was ONCOPATH founded?
ONCOPATH was founded on 21-01-2015.
Is ONCOPATH still active?
Yes, ONCOPATH is an active enterprise in the KBO register.
What is the turnover of ONCOPATH?
The turnover in financial year 2025 is about €310,000. This figure is estimated from the gross margin of €164,263 and 40 comparable companies (NACE 86220). It probably lies between €260,000 and €410,000. In financial year 2023 turnover was €226,778.Financials
Is ONCOPATH profitable?
In financial year 2025, ONCOPATH made a profit of €85,312.
Where can I find the annual accounts of ONCOPATH?
ONCOPATH filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of ONCOPATH due?
ONCOPATH must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.